论文部分内容阅读
目的:探讨中医肾消通络方联合前列地尔治疗Ⅳ期糖尿病肾病的临床效果。方法:79例Ⅳ期糖尿病肾病患者以随机数表法分为中西医组(n=40)和西医组(n=39),西医组实施前列地尔治疗方案,中西医组在对照组基础上给予肾消通络方治疗。治疗前后检测血脂、血糖水平,主要包括总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及和高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)、糖化血红蛋白(Hb A1c);治疗前后检测肾功能指标,主要包括测定血肌酐(SCr)、血尿素氮(BUN)、免疫球蛋白G(IgG)及尿白蛋白排泄率(UAER),并评估两组治疗疗效及安全性。结果:两组治疗前血脂、血糖、肾功能指标比较无统计学意义(P>0.05),治疗后血脂、血糖及肾功能指标水平均明显改善(P<0.05),且治疗后中西医组TC、LDL-C、FBG水平均显著低于西医组(P<0.05),SCr、BUN、IgG、UAER水平显著低于西医组(P<0.05)。中西医组临床治疗总有效率82.50%显著高于西医组61.54%(P<0.05)。两组均未发生明显的不良反应症状。结论:肾消通络方联合前列地尔治疗Ⅳ期糖尿病肾病的临床疗效显著,具有改善患者血脂血糖水平和临床症状、保护肾功能作用。
Objective: To investigate the clinical effect of traditional Chinese medicine Xiaoxuetongluo combined with alprostadil on stage Ⅳ diabetic nephropathy. Methods: 79 patients with stage Ⅳ diabetic nephropathy were divided into two groups according to the random number table: traditional Chinese and western medicine group (n = 40) and western medicine group (n = 39). Western medicine group was treated with alprostadil. Based on the control group Give kidney Xiao Tong Fang treatment. Blood lipid and blood glucose levels were measured before and after treatment, including TC, LDL-C and HDL-C, FBG, Hb A1c ) Before and after the treatment of renal function indicators, including the determination of serum creatinine (SCr), blood urea nitrogen (BUN), immunoglobulin G (IgG) and urinary albumin excretion rate (UAER), and evaluate the efficacy and safety of the two groups Sex. Results: Before treatment, there was no significant difference in the indexes of blood lipids, blood glucose and renal function between the two groups (P> 0.05). After treatment, the levels of blood lipids, blood glucose and renal function were significantly improved (P <0.05) , LDL-C and FBG levels were significantly lower than those in western medicine group (P <0.05). SCr, BUN, IgG and UAER levels were significantly lower than those in Western medicine group (P <0.05). The total effective rate of clinical treatment of Chinese and Western medicine group was 82.50%, significantly higher than that of Western medicine group (61.54%, P <0.05). No obvious adverse reaction symptoms occurred in both groups. Conclusion: The therapeutic effect of Shenxuetongluo combined with alprostadil on the treatment of stage Ⅳ diabetic nephropathy is significant. It has the effects of improving the blood lipid, blood sugar level and clinical symptoms of patients and protecting renal function.